Sun Pharma is a large pharma headquartered in India. Over the past three years, Sun Pharma has been involved in 4 licensing and acquisition transactions, with a primary focus on Antibodies (2 deals). The company currently has 4 active clinical trials, primarily in Mega Deals.
Deals (12mo)
5
Active Trials
4
Top Modality
Antibodies
Focus Area
Mega Deals
Licensing, acquisition, and partnership transactions involving Sun Pharma in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Checkpoint oncology assets | Sun Pharmaceutical Industries | Antibodies | Unknown | acquisition | May 2026 |
| Organon (full company) | Sun Pharmaceutical Industries | Other | Approved | acquisition | May 2026 |
| deuterated JAK inhibitor | Sun Pharmaceutical | Small Molecules | Phase 3 | acquisition | Jun 2025 |
Therapeutic areas and modalities where Sun Pharma is most active based on deal history and clinical trial data.
Key indicators of Sun Pharma's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Acquisition Appetite
Strategic Priorities
Sun Pharma has 4 active clinical trials across 2 development phases.
2
Phase 1
2
Phase 2
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Mega Deals assets — powered by data from 3,500+ real biopharma transactions.
Dermatology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for dermatology
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Sun Pharma is a large pharma company based in India that has been actively engaged in licensing transactions across the biopharma landscape. With 4 deals over the past three years, Sun Pharma ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Sun Pharma include Mega Deals (4 deals and trials), Dermatology (3 deals and trials), CNS Disorders (1 deal and trial), and Hematological Malignancies (1 deal and trial). In terms of modality, Sun Pharma has shown particular interest in antibodies, other, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Sun Pharma and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Sun Pharma's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.
Industry-wide analysis of deal terms, trends, and market dynamics
© 2026 Ambrosia Ventures. All rights reserved.
Benchmarks powered by 1,900+ real biopharma licensing deals